Intrathecal Dexmedetomidine as Adjuvants to Low Dose of Ropivacaine in Hysteroscopic Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004961

Enrollment

Unknown

Registered

2014-07-12

Start date

2013-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopic Surgery

Interventions

RD:intrathecal ropivacaine supplemented with dexmedet

RF:intrathecal ropivacaine supplemented with fentanyl

R group:intrathecal ropivacaine

Eligibility

Sex/Gender

Female

Age

19 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients to be aged 19 to 50 yrs, ASA I~II, undergoing elective hysteroscopic surgery were enrolled in the study.

Exclusion criteria

Exclusion criteria: Patients who refused spinal anesthesia, had any contraindication to regional anesthesia, bradycardia, opioids addiction, older than 55 years old, had any major co-morbidity were excluded from this study.

Design outcomes

Primary

Measure	Time frame
effect;adverse effec;	—

Countries

China

Contacts

Public ContactLi Yuantao

sylyt6788@sina.com+86 15013857589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026